Avid Bioservices Inc (CDMO)

[cjgaddy]

3-17-18: First Analysis’s EPS Est’s for next 5qtrs. Where does a coverage company like First-Analysis come up with their numbers? Thru discussions with mgt? Just Swags? (assuming stocknewstimes is reporting accurately). I wish we could get the Wells Fargo estimates for comparison.

3-17-18: First Analysis forecasts Avid Bioservices Inc (CDMO) Forecasted to Earn FY2018 Earnings of ($.69)/share
Posted by Andrew Steele
https://stocknewstimes.com/2018/03/17/avid-bioservices-inc-cdmo-forecasted-to-earn-fy2018-earnings-of-0-69-per-share.html
Stock analysts at First Analysis issued their FY2018 earnings/sh. (EPS) estimates for Avid Bioservices (CDMO) in a research note issued to investors on 3-13-18. They anticipate that the biopharmaceutical company will post earnings of ($.69)/sh. for FY’18. First Analysis currently has an “Overweight” rating/$4.00/PT. Est’s for Avid Bioservices:
Q4/FY’18 ($.08)
...FULL FY’18: ($.69) - FY’18 ends 4-30-18
Q1/FY’19 ($.06)
Q2/FY’19 ($.05)
Q3/FY’19 ($.03)
Q4/FY’19 ($.01)
...FULL FY’19: ($.15) - FY’19 ends 4-30-19

= = = = = = = = =
3-13-18: Avid Bioservices initiated @Overweight/$4 by First Analysis
First Analysis analyst Steven Schwartz [and 2nd analyst, Tracy Marshbanks] started Avid Bioservices with an Overweight rating and $4 price target. The analyst views the company as a "compelling opportunity for investors with a longer-term investment horizon." He views current valuation levels as attractive and sees revenue growth rates eventually exceeding 10% with faster profit growth driven by scale efficiencies.
StreetInsider: “Analyst Schwartz sees a successful shift to a pure-play CDMO.”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=139264676

= = = = = = = = = = =
3-15-18: “Wells Fargo Starts Avid Bioservices (CDMO) at Outperform, 'A Biologic Contract Manufacturing Pure Play'”
Wells Fargo initiates coverage on Avid Bioservices (NASDAQ: CDMO) with a Outperform rating and a price target of $3.50.
StreetInsider.com: https://tinyurl.com/yd2c3e83
RESEARCH: https://www.wellsfargo.com/com/securities/research
https://www.wellsfargoresearch.com/Public